MET and renal cell carcinoma: In a phase II study with RCC, interestingly, therapeutic response of foretinib (a multi-kinase inhibitor targeting c-Met, VEGF, RON, AXL, and TIE-2 receptors) was closely associated with the germline MET mutations [12].